A recent study linked Alzheimer’s to benzodiazepine usage. The findings are striking. Taking the drug for three to six months raised the risk of developing Alzheimer’s by 32%, and taking it for more than six months boosted the risk by 84%. In the study, the greater people’s cumulative dose of benzodiazepines, the higher their risk.
A second study from the University of Washington with conflicting outcomes came out refuting the risk, stating that only those on moderate or lower doses developed Alzheimer’s.
We were expecting to find a higher risk only in those individuals that had high use of benzodiazepines. So contrary to our expectations, we did find the small increased risk for dementia in people with low or moderate use.
Some notable things immediately stood out as missing from that secondary study. They found high doses and no doses were evenly correlated with Alzheimer’s. The lower and medium doses were correlated. One guess is possibly the lower and medium doses are daily users, while the higher doses were not. None of this was clarified. It seems essential to state the length of time and dosing for an accurate picture. However, this study did not. “The investigators were unable determine the impact of the use of individual benzodiazepines on dementia risk.” Because of this, the title Benzodiazepines: No Dementia Risk? seems misleading.
The study also did not quantify what constitutes a “low dose“, “high dose”, or “medium dose” of a benzodiazepine. That seems pertinent as well to be a sound study. It was also not known if the control participants who developed Alzheimer’s were ever users of benzodiazepines. They did not ask that when qualifying the control. The sample only included a few participants that had ‘heavy” benzodiazepine use, and overall, the participants might have had lower levels of exposure than in some other studies.
So where is the truth? What is the best course of action? It would be irresponsible to dismiss the first study for the second study, but we recommend seeking further studies, specifically on those taking benzodiazepines daily, regardless of the size of the dose.
JC is a graduate of the University of South Florida. Prior to becoming sick from benzodiazepines she was working on her Master’s in Clinical Psychology. She founded Benzodiazepine Information Coalition in 2016 after sustaining a multi year injury from prescription Ativan taken as instructed by her physician. She experienced severe side effects from the drug and was misdiagnosed, over a 4 year period, with a multitude of health problems from multiple specialists unable to consider benzodiazepines as the culprit. When she finally discovered the cause of these problems she was unable to find a physician, despite multiple consultations, capable of tapering her off the drug. Fortunately she was able to find this information online from other laypeople who had experienced the same problem. Shocked with, and confused by, the widespread lack of knowledge within the medical community about such a commonly prescribed class of drugs, along with a feeling of indebtedness towards the prescribed harm community that saved her, she decided to organize and form a coalition to facilitate information sharing, awareness, education, research and change.